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Abstract. Polycyclic aromatic hydrocarbons (PAHs) are considered to be significant environmental carcinogens. Additionally,
various planar ring systems are capable of intercalating with
DNA, leading to a number of drugs that possess chemotherapeutic activity. In this study, three new polyaromatic compounds
with a side chain were synthesized, and spectroscopic as well
as elemental analyses were performed. The addition of the
long chains to either chrysene or pyrene caused a red-shift in
the spectral emission when compared to the corresponding
polycyclic aromatic hydrocarbons itself. Furthermore, the
cytotoxicity of the three novel polyaromatic compounds was
evaluated in vitro in a panel of cultured mammalian cell lines.
The pyrenyl ether demonstrated better cytotoxicity compared
to cisplatin against colon (HT-29) as well as cervical (HeLa)
cancer cell lines. In conclusion, three new compounds were
synthesized and investigated in this study. This novel method is
likely to play a role in other areas of research.
Introduction
Polycyclic aromatic hydrocarbons (PAHs) are widely
distributed in nature and are considered to be significant environmental carcinogens. Although they are generally formed at
high temperatures, PAHs should be considered as biologically
inactive. The major sources of these hydrocarbons include, but
are not limited to, power plants, gasoline, coal tar and diesel
engines. PAHs are soluble in lipid, can be metabolized and
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are capable of interacting with cellular components, such as
protein and nucleic acid. The metabolic activation of PAH
is responsible for their carcinogenic properties. Since PAHs
require metabolic activation, they are considered to be indirect
acting carcinogens (1). On the other hand, DNA intercalators,
an important class of antitumoral DNA binders, are characterized by the insertion of planar aromatic or heteroaromatic rings
between DNA base pairs (2,3), as in the case of anthracyclines,
acridines and ellipticines (4,5), which are thought to poison
topoisomerases I and II (6). Various factors are involved in the
stabilization of the drug-DNA complex, of which hydrogen
bonding and π -stacking are the most important. Moreover,
PAHs constitute an important class for the design of new
chemotherapeutic DNA intercalators (7,8).
PAH-containing anticancer compounds were first reported
to be present in either the anthracene (8-11) or the pyrene ring
systems (1,12-14). DNA-binding molecules are considered to be
an important class of drugs in anticancer therapy (15). Although
it is well-established that DNA binding is not sufficient to confer
cytotoxic activities, interaction with DNA is often considered
a necessary criterion for maintaining a cytotoxic effect. The
antitumoral anthracyclines daunorubicin and doxorubicin and
the synthetic anthracene-9,10-dione mitoxantrone are potent
agents in clinical use at present, with broad application in the
treatment of several leukemias and lymphomas as well as in
combination chemotherapy of solid tumors (16,17).
It is well-known that cancer is the leading cause of death in
people under the age of 85 in the United States, and mortality
from this disease appears to be on the increase (18). Therefore,
it is imperative to develop new compounds and strategies to
decrease the incidence and mortality of cancer. As a part of
our ongoing research (7,19-29) to synthesize new PAH-bearing
anticancer agents, we report the synthesis and in vitro cytotoxic evaluation of certain new PAH compounds (Fig. 1).
Materials and methods
Materials. The following materials were obtained for the study:
PAH (chrysene and pyrene), bismuth nitrate pentahydrate,
montmorillonite KSF clay, indium, ammonium chloride,
isobutyl chloroformate, 1.0 M borane in tetrahydrofuran,
reagent grade solvents (Aldrich Chemical Co., St. Louis,
MO, USA), dimethylsulfoxide (DMSO; Sigma-Aldrich Corp.,
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St. Louis, MO, USA), phosphate-buffered saline (PBS),
Dulbecco's modified Eagle's medium (DMEM) (Invitrogen,
Carlsbad, CA, USA), fetal bovine serum (FBS; Invitrogen),
McCoy's media (Invitrogen) and doxorubicin (Fisher Scientific,
Pittsburgh, PA, USA).
Synthesis of the compounds 1, 2 and 3. Melting points were
determined in a Fisher Scientific electrochemical Mel-Temp*
manual melting point apparatus (Model 1001) equipped with
a 300˚C thermometer. Elemental analyses (C, H, N) were
conducted using the Perkin-Elmer 2400 series II elemental
analyzer. Their results were found to be in agreement (±0.2%)
with the calculated values for C, H, N. FT-IR spectra were registered on a Bruker IFS 55 Equinox FT-IR spectrophotometer
as KBr discs. 1H-NMR (300 MHz) and 13C-NMR (75.4 MHz)
spectra were obtained at room temperature with JEOL Eclipse300 equipment using TMS as an internal standard and CDCl3
as a solvent. Analytical grade chemicals (Sigma-Aldrich
Corp.) were used throughout the study. Deionized water was
used for the preparation of all aqueous solutions.
PAH nitration. Chrysene or pyrene (1 mmol) and montmorillonite KSF clay (500 mg; Aldrich Chemical Co.) were added
to a suspension of bismuth nitrate pentahydrate (1 mmol) in
anhydrous dichloromethane (10 ml). The solvent was then
evaporated under reduced pressure and the reaction mixture
was irradiated in a kitchen microwave for 6 min (2x3 min).
After every 2 min the reaction was monitored by TLC. After
completion of the reaction, the reaction mixture was washed
with dichloromethane (3x5 ml) and the solvent was evaporated
by reduced pressure distillation. The pure product was isolated
by crystallization from a dichloromethane/hexanes mixture in
excellent yield (>90%).
Reduction of the nitrated PAH to the corresponding amine.
The nitrated PAH (1 mmol) and indium (570 mg), 2.5 ml
ethanol and 2.5 ml 20% aqueous ammonium chloride solution
were refluxed vigorously for 24 h (monitored by TLC). After
completion of the reaction, the mixture was filtered through
a Büchner funnel and the filtrate was extracted with dichloromethane (2x3 ml). The dichloromethane layer was washed
with brine and water successively and dried over anhydrous
sodium sulfate. The pure amine was isolated by crystallization
from a dichloromethane/hexanes mixture in excellent yield
(>80%).
Coupling of the polyaromatic amines with isobutyl chloroformate. The polyaromatic amine (1 mmol) was stirred with
triethylamine (3 mmol) in anhydrous dichloromethane (5 ml)
at a temperature of -5 to 0˚C, (1.8 mmol in 2 ml anhydrous
dichloromethane) was then added dropwise. Following the
addition of Isobutyl chloroformate, the mixture was agitated
for 24 h (monitored by TLC). After completion of the reaction,
the mixture was washed with a saturated solution of sodium
bicarbonate, brine and water successively. The pure product
was isolated after column chromatography over silica gel
(>70% yield).
Reduction of 2 to 3. Compound 2 (1 mmol) was refluxed
with 6 ml of 1.0 M borane/tetrahydrofuran solution for 36 h.
Then, 5 ml of 4% hydrochloric acid solution was added and the
mixture was again refluxed for another 24 h. After completion
of the reaction, the pH of the solution was maintained at ~7.0 by
10% aqueous sodium hydroxide solution and the mixture was

Figure 1. Synthesis of the compounds 1, 2 and 3.

extracted with ethyl acetate (3x3 ml). The organic layer was
washed with brine and water successively. The pure product
(compound 3) was isolated after column chromatography over
silica gel (78% yield).
Isobutyl chrysen-6-ylcarbamate (compound 1). mp 181˚C;
IR (KBr disc, cm-1): 3278, 3269, 1695, 1535, 1239, 1165, 972,
829; 1H-NMR δ (CDCl3, ppm): 0.99 (m, 6H, methyl), 2.00 (m,
1H, methine), 3.98 (m, 2H, methylene), 7.19 (broad s, NH),
7.89-8.09 (m, 11H, Ar-H); 13C-NMR (CDCl3, ppm) δ: 19.56
(2C), 28.40, 70.76, 111.98, 119.78, 122.43, 122.47, 126.54,
126.87, 126.89, 126.94, 126.98, 127.07, 127.98, 128.65, 128.69,
129.87, 129.98, 130.08, 131.86, 131.99, 156.51. Anal. Calcd. for
C23H21NO2: C, 80.44; H, 6.16; N, 4.08. Experimental: C, 80.30;
H, 6.10; N, 3.91.
Isobutyl pyren-4-ylcarbamate (compound 2). mp 146-148˚C;
IR (KBr disc, cm-1): 3282, 3276, 1696, 1560, 1527, 1241, 1112,
971, 865; 1H-NMR δ (CDCl3, ppm): 1.01 (m, 6H, methyl),
2.03 (m, 1H, methine), 4.06 (d, 2H, J= 6.49 Hz, methylene),
7.21 (broad s, NH), 7.98-8.14 (m, 9H, Ar-H); 13C-NMR
(CDCl3, ppm) δ: 19.23 (2C), 28.14, 71.89, 120.12, 124.87,
124.97(2C), 125.23 (2C), 125.35, 125.42 (2C), 126.21, 126.66,
127.39, 127.88, 130.70, 130.92, 131.49, 155.11. Anal. Calcd. for
C21H19NO2: C, 79.47; H, 6.03; N, 4.41. Experimental: C, 79.31;
H, 5.91; N, 4.22.
N-(isobutoxymethyl)pyren- 4-amine (compound 3). mp
76-78˚C; IR (KBr disc, cm-1): 2692, 2669, 2643, 2358, 1600,
1514, 1282, 827; 1H-NMR δ (CDCl 3, ppm): 0.94 (m, 6H,
methyl), 2.08 (m, 1H, methine), 3.01 (m, 2H, methylene), 3.30
(m, 2H, methylene), 4.71 (broad s, NH), 7.31-8.06 (m, 9H,
Ar-H); 13C-NMR δ (CDCl3, ppm): 21.88, 28.17, 31.24, 108.27,
116.53, 119.44, 122.45, 123.03, 123.24, 123.36, 123.87, 124.21,
125.71, 125.84, 126.01, 126.36, 126.54, 126.76, 127.12, 127.93,
143.59. Anal. Calcd. for C21H21NO: C, 83.13; H, 6.98; N, 4.62.
Experimental: C, 82.89; H, 6.61; N, 4.51.
Spectral analyses of the compounds 1, 2 and 3. Compounds 1,
2 and 3 were dissolved in DMSO at a concentration of 20 mM.
For spectral analyses, compounds were then diluted to 50 µM
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Figure 2. Emission spectrum of the compound 2 [compound (50 µM) was
diluted in PBS and excited at a wavelength of 350 nM].
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Figure 4. Emission spectrum of the compound 1 [compound (50 µM) was
diluted in PBS and excited at a wavelength of 350 nM].

SigmaPlot software (Systat Software, Inc., Chicago, IL, USA).
Each compound was synthesized in two independent reactions
and used in cell viability assays to generate dose-response
curves. The mean IC50 (in µM), with the corresponding standard deviation of the two independent synthesis reactions, was
then calculated.

Figure 3. Emission spectrum of the compound 3 [compound (50 µM) was
diluted in PBS and excited at a wavelength of 350 nM].

in either DMSO or PBS. The absorbance of each compound,
dissolved in either DMSO or PBS, was then analyzed between
the wavelengths of 350-700 nM using a SpextraMaxM5
plate reader (Molecular Devices, Sunnyvale, CA, USA).
In addition, diluted compounds were excited with light at a
wavelength of 350 nM, and the subsequent light emission was
analyzed between the wavelengths of 350-700 nM using a
SpextraMaxM5 plate reader.
Mammalian cell culture. HepG2, Hepa1-6, NIH3T3 and
HeLa cells were cultured in DMEM (Invitrogen) containing
10% FBS (Invitrogen), Caco-2 cells were cultured in DMEM
containing 20% FBS and HT-29 cells were cultured in McCoy's
media (Invitrogen) containing 10% FBS. The cell lines were
purchased from American Type Culture Collection (ATCC;
Manassas, VA, USA) and incubated at 37˚C with 5% CO2.
Mammalian cell viability assay. Cells were plated onto a
96-well dish (5,000 cells/well) and incubated overnight at
37˚C. The following day, cells were treated with increasing
dosages (3-100 µM) of each compound, which had been
dissolved in DMSO. The DMSO concentration of treatments
was limited to 0.5%, and cells were treated with DMSO alone
(0.5%) or 10 µM doxorubicin as negative and positive controls
for cytotoxicity, respectively. After 48 h, cells were fixed
and cell viability was analyzed using the Sulforhodamine B
colorimetric assay as previously described (30). Absorbance
of SRB was measured utilizing a SpextraMaxM5 plate reader
and absorbance values were normalized to non-treated cells.
The normalized cell viability with increasing drug doses
was plotted on a four-parameter logistical curve, and the
IC50 of each compound in each cell line was calculated using

Subcellular localization. Cells (7,200 cells/well) were plated
onto Nunc Lab-TekII 8-chamber slides (Fisher Scientific) and
incubated overnight at 37˚C. The following day, cells were
treated with compound (50 µM) for 4 h. After treatment,
cells were fixed with PBS containing 4% formaldehyde for
25 min at room temperature. Then, they were permeabilized
using PBS containing 0.2% Triton-X-100 for 5 min at room
temperature and mounted using VectaShield mounting medium
containing DAPI (Fisher Scientific). The cells were visualized
using a Zeiss AxioImager.Z1 epifluorescent microscope (Carl
Zeiss Microimaging, LLC, Thornwood, NY, USA) with EGFP
(Excitation 470/40; Emission 525/50) and DAPI filters, and
images were acquired using AxioVision Rel. 4.6 software
(Zeiss).
Results and Discussion
Spectral emission of the compounds 1, 2 and 3. Previous
reports have identified that the peak emission wavelength of
pyrene is less than 400 nM, with a shoulder for that emission
peak at approximately 420 nM (31,32). Similarly, chrysene was
previously shown to exhibit a peak emission wavelength of less
than 400 nM, with a shoulder for its emission peak at approximately 425 nM (33). Therefore, we aimed to determine whether
PAH derivatives 1-3 would have an impact on the absorption
and spectral emission patterns of these molecules. Although
no significant absorbance was detected for compounds in this
study, i.e., compounds 1, 2 and 3, at wavelengths between 350
and 650 nM, we detected a fluorescence emission spectrum for
each of the PAH derivatives. The peak emission wavelength
for both isobutyl pyren-4-ylcarbamate (compound 2) and
N-(isobutoxymethyl)pyren-4-amine (compound 3) occurred
between 460 and 470 nM (Figs. 2 and 3). However, isobutyl
chrysen-6-ylcarbamate (compound 1) exhibited a much smaller
emission spectra (Fig. 4), with shoulders for its peak at 420
and 525 nM, when compared to compounds 2 and 3 (ig. 4 vs.
Figs. 1 and 2). The limited fluorescence of this compound was
possibly due to its crystallizing in aqueous solution, since this
emission peak was larger, albeit at the same wavelength, when
compound 3 was dissolved in an organic solvent, DMSO (data
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Table I. Estimated IC50 values (in µM) for the compounds 1, 2 and 3 in a small panel of mammalian cell lines.
Compounds
1
2
3
Cisplatin

HepG2
31.8±12.6b
30.4±5.0
39.6±7.1
7.0

Hepa1-6

Caco-2

HT-29

HeLa

NIH3T3

9.1±9.1
5.9±2.5
9.9±5.2
4.0

>50
36.3±3.6
>50
10.8

30.5±10.0
20.7±3.8
14.0±5.7
16.8

10.5±3.80
16.2±3.80
9.8±1.03
11.7

16.4±5.1
13.5±11.6
12.5a
8.5

Based on single dose-response curve. bMinimum of curve is ≥35% cell viability.

a

Figure 5. Subcellular localization of compound 3. HepG2 cells were treated
with 50 µM of compound 3 as described in Materials and methods. The
compound accumulated in a punctate pattern (shown in green) outside of the
nucleus (indicated by white arrows in the left panel and DAPI staining in the
right panel).

not shown). Nonetheless, these data indicate that the addition of
the long chains to either chrysene or pyrene caused a red-shift
in spectral emission when compared to the PAHs (chrysene or
pyrene).
Decreasing viability of multiple mammalian cell lines.
Previous reports from our group and from other authors have
shown that certain derivatives of PAHs, including pyrene and
chrysene derivatives, reduce the viability of transformed cell
lines (1,20,34), and some of these PAH derivatives have been
reported to reduce cell viability by induction of apoptosis
(34,35). Therefore, we tested the effects of compounds 1, 2 and 3
on the viability of a small panel of human and mouse cell lines,
including liver cancer cell lines (HepG2 and Hepa1-6), colon
cancer cell lines (HT-29 and Caco-2), a cervical cancer cell line
(HeLa) and NIH3T3 cells. Colon cancer and the HepG2 liver
cancer cell lines were less susceptible to the effects of the three
compounds when compared to other cell types; Caco-2 cells
proved to be particularly resistant to the effects of these three
compounds (Table I).
However, each compound was capable of reducing the
viability of Hepa1-6, HeLa and NIH3T3 cells with an estimated
IC50 value of 16 µM or lower (Table I). Although compound 2
was generally slightly more cytotoxic than compound 1,
little difference in cytotoxicity was noted when comparing
the pyrene (2) and chrysene (1) PAH-coupled compounds.
Similarly, little difference in cytotoxicity was observed when
comparing compounds 2 and 3, suggesting that reduction of

the carbamate group had little effect on the pyrene-coupled
PAHs.
Since each of the three compounds was capable of reducing
cell viability, at least of certain cancer and non-cancer cell
lines, we also aimed to determine whether this reduction in
cell viability occurred through the induction of apoptosis.
We examined whether compounds 1, 2 and 3 treatment led to
increased caspase 3/7 activity or increased DNA fragmentation
(as measured by a TUNEL assay). We did not detect an increase
in either of these apoptotic features in either HepG2 or Hepa1-6
cells in response to treatment with any of the three compounds
analyzed (data not shown). Taken together, these data suggest
that the ability of compounds 1, 2 and 3 to reduce cell viability
occurs through an apoptosis-independent mechanism.
A wide variety of planar ring systems are capable of
intercalating with DNA, giving rise to many drugs that
possess chemotherapeutic activity. In this context, three new
polyaromatic derivatives containing polar side chains were
systematically synthesized and investigated. The primary
mode of action of these intercalators is believed to be their
reversible binding to nuclear DNA, which causes inhibition of
the replication process and, thus, cell death. As is well-known,
cytotoxicity is not only dependent on the ability to interact
with DNA. Instead, the drug must be capable of interacting
with DNA to form a stable ternary DNA-intercalator-enzyme
complex with a relatively long half-life in such a way that the
enzymatic process cannot progress (11). Therefore, the low
level of cytotoxicity observed for compounds 1-3 may be
ascribed to an inability to access nuclear DNA or a low binding
association (including a low affinity or highly transient interaction) to DNA.
Polyaromatic compounds 1-3 accumulate outside the cell
nucleus. To determine whether the three novel polyaromatic
compounds (i.e., compounds 1-3) were capable of accessing
the nuclear DNA of cells, we examined their auto-fluorescent
properties. HepG2 cells were treated with each compound (50
µM). Cells were then fixed, stained with DAPI and observed
using an epifluorescent microscope. Each of the three
compounds was capable of being detected using a filter for
enhanced green fluorescent protein, in accordance with their
spectral emission properties (Figs. 2-4). We did not detect
any of the three polyaromatic compounds in cell nuclei under
these conditions, although compounds 1 and 2 formed crystals at these concentrations (data not shown). Interesetingly,
compound 3 accumulated in a punctate pattern outside
the cell nuclei (Fig. 5). This pattern is similar to a previous
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study (34) showing that a pyrene derivate accumulated in
the cytosol of cells. These data suggest that the low level of
cytotoxicity observed for these compounds is more likely due
to their inability to access nuclear DNA in cells rather than
a low binding affinity for DNA, although no studies have
been performed to assess the DNA binding affinity of these
compounds.
In conclusion, the present synthetic protocol allows for the
preparation of three new polyaromatic compounds. Structure
elucidation was carried out by various spectroscopic as well as
elemental analyses. The addition of the long-chains to either
chrysene or pyrene caused a red-shift in spectral emission
when compared to the corresponding PAH itself. Furthermore,
the cytotoxicity of the three novel polyaromatic compounds
was evaluated in vitro in a panel of mammalian cell lines.
Results showed that compound 2 exhibited better cytotoxicity compared to cisplatin against the HeLa cancer cell line,
whereas compound 3, the pyrenyl ether, demonstrated better
cytotoxicity against colon (HT-29) as well as cervical (HeLa)
cancer cell lines. In summary, three new and promising anticancer PAH derivatives have been synthesized, and structural
modification of these compounds is in progress. In addition,
the method for synthesis of compounds 1-3 reported in this
study may have applications in other areas of research.
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